Stockscreener 앱 받기
0.00
100.00%
-2.65
시간 외 거래:
2.65
2.65
+
전일 마감가:
$2.65
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$114.24M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
0.00
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
0.00 | 114.24M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 개시 | CapitalOne | Overweight |
| 2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-17 | 재개 | Goldman | Buy |
| 2021-09-23 | 개시 | Stifel | Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2021-06-28 | 개시 | Guggenheim | Buy |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2020-10-28 | 개시 | Northland Capital | Outperform |
| 2020-07-14 | 개시 | Cowen | Outperform |
| 2020-07-14 | 개시 | Goldman | Neutral |
| 2020-07-14 | 개시 | Morgan Stanley | Overweight |
| 2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics announces shareholder meeting for acquisition approval - MSN
RPTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Repare Therapeutics Inc. stock benefit from infrastructure spendingCEO Change & Expert Curated Trade Ideas - mfd.ru
Is Repare Therapeutics Inc forming a bullish divergenceForecast Cut & Low Volatility Stock Recommendations - baoquankhu1.vn
Will Repare Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Spike Watch & Risk Controlled Swing Trade Alerts - mfd.ru
[15-12G] Repare Therapeutics Inc. SEC Filing - Stock Titan
How Repare Therapeutics Inc. stock reacts to oil prices2025 Price Targets & Verified Technical Trade Signals - mfd.ru
Is Repare Therapeutics Inc. stock heavily shortedMarket Risk Summary & AI Driven Price Forecasts - mfd.ru
Why Repare Therapeutics Inc. stock could outperform in 2025July 2025 Market Mood & Safe Capital Growth Tips - mfd.ru
Is Repare Therapeutics Inc. stock a smart buy before Fed meetingEarnings Beat & Community Shared Stock Ideas - mfd.ru
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Gilead’s Growing Oncology Role Reshapes The Investment Case For GILD - Sahm
Published on: 2026-02-02 06:19:02 - baoquankhu1.vn
Shay Capital LLC's Strategic Acquisition of Repare Therapeutics Inc Shares - GuruFocus
Repare Therapeutics completes acquisition and goes private - The Globe and Mail
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January - MarketBeat
Repare Announces Completion of Acquisition by XenoTherapeutics - citybiz
Repare Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
RPTX Technical Analysis & Stock Price Forecast - Intellectia AI
Repare Shareholders Approve Acquisition by XenoTherapeutics - citybiz
Repare Shareholders approve acquisition by XenoTherapeutics - Medical Buyer
Repare Therapeutics (RPTX) Shareholders Approve Acquisition by X - GuruFocus
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - Investing News Network
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics - TipRanks
99.76% of Repare voters back takeover by nonprofit XenoTherapeutics - Stock Titan
Bank Watch: Is Repare Therapeutics Inc stock heavily shorted2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update - MarketBeat
Update Report: Is Repare Therapeutics Inc stock heavily shorted2025 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4%Here's Why - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why - Defense World
Levels Update: Is Repare Therapeutics Inc. stock a top pick in earnings season2025 Sector Review & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Opening: Will Repare Therapeutics Inc stock attract ESG investorsMarket Sentiment Summary & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Insider Trends: Why Repare Therapeutics Inc. stock is in analyst buy zonePortfolio Update Report & Capital Efficient Trading Techniques - Bộ Nội Vụ
Published on: 2026-01-13 02:16:07 - baoquankhu1.vn
What catalysts could drive Repare Therapeutics Inc. stock higherTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Oklahoma City NewsThe OklahomanRepare Therapeutics Inc.Common Shares (Nasdaq:RPTX) Stock Quote - FinancialContent
Is Repare Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Review & Risk Managed Trade Strategies - Улправда
Can Repare Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Will Repare Therapeutics Inc. stock benefit from commodity prices2025 Big Picture & Momentum Based Trading Signals - ulpravda.ru
Repare Therapeutics sells RP-3467 cancer program assets to Gilead for up to $30 million - MSN
Can Repare Therapeutics Inc. stock double in next 5 yearsVolatility Adjusted Trading & Learn to Trade with Real-Time Feedback - Улправда
Repare Therapeutics Inc.Common Shares (NQ: RPTX - FinancialContent
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
PYXS,RPTX Dividends - Finviz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout - TipRanks
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):